Pancreatic cancer is the most malignant tumor among the malignant tumors of the digestive system, known as the king of cancer, but there is no particularly effective targeted drug therapy for pancreatic cancer, and research has confirmed that it may be effective, such as troche, which is also known as erlotinib hydrochloride may be effective, each course of treatment is four boxes of drugs, a box of seven capsules, the price of each grain is more than 20-80. If you can use can try to use, but the specific can play how much effect is not good to determine. Other targeted drugs such as Apatinib, which is a domestic drug, can also be used for targeted treatment of pancreatic cancer, for example, Apatinib may cost 6,000-7,000 yuan per course, but because pancreatic cancer is not a targeted indication for this drug, it is not generally reimbursed by medical insurance. Also PARP inhibitor olaparib may be effective for patients with BRCA mutation and larotinib for NTRK fusion gene positive patients.